Skip to content

The feasibility study of miR-200c-3p in the diagnosis and treatment of endometrial carcinoma

The feasibility study of miR-200c-3p in the diagnosis and treatment of endometrial carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDD-17013391
Enrollment
Unknown
Registered
2017-11-15
Start date
2017-12-25
Completion date
Unknown
Last updated
2017-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial carcinoma

Interventions

Gold Standard:pathologic diagnosis
Index test:miR-200c-3p

Sponsors

The Sixth Hospital of Shanghai
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 85 Years

Inclusion criteria

Inclusion criteria: Experimental group: All patients should meet the diagnosis criteria of endometrial carcinoma and will be inpatients for surgery; Control group: All the other patients for surgery that are not the patients of endometrial carcinoma. Both the two groups of patients should suit the exclusion criteria.;Inclusion criteria: Experimental group: All patients should meet the diagnosis criteria of endometrial carcinoma and will be inpatients for surgery; Control group: All the other patients for surgery that are not the patients of endometrial carcinoma. Both the two groups of patients should suit the exclusion criteria.

Exclusion criteria

Exclusion criteria: (1)Pregnant women; (2) Patients who combine other malignancies(cervical cancer, fallopian tube cancer, ovarian cancer , etc); (3) Other special types of treatment were used before the experiment: chemo-radiotherapy, progesterone therapy, etc; (4) Combine with rheumatic immune diseases.;Exclusion criteria: (1)Pregnant women; (2) Patients who combine other malignancies(cervical cancer, fallopian tube cancer, ovarian cancer , etc); (3) Other special types of treatment were used before the experiment: chemo-radiotherapy, progesterone therapy, etc; (4) Combine with rheumatic immune diseases.

Design outcomes

Primary

MeasureTime frame
miR-200c-3p;;miR-200c-3p;

Countries

China

Contacts

Public ContactYang Bingqing;Yang Bingqing ;

The Sixth Hospital of Shanghai;The Sixth Hospital of Shanghai

1003870838@qq.com;1003870838@qq.com+86 13651824118;+86 13651824118

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026